IGFBP3 and Alzheimer disease: MR studies are not prone to these typical biases (but come with separate limitations).13 Hence, the lack of AD risk difference according to genetically predicted variations in IGF1, IGFBP3, and the molar ratio of these suggests that previous observational evidence implicating these circulating IGF peptides in AD etiology may have been misleading.